PredimiR
Kit for predicting and monitoring response to treatment in ovarian cancer
This technology has been patented since 2018, extended in Australia, Canada , China, Europe, Japan and USA.
Description
Ovarian cancer is one of the deadliest cancers in women worldwide. Ovarian cancer recurrence is difficult to predict and acquisition of resistance to platinum-based chemotherapy is responsible for a low survival rate at five years (<30%). This situation should change with the emergence of targeted therapies, which have proved particularly effective. However, clinicians lack the clinical tools to predict and monitor the efficacy of both conventional and innovative treatments.
The PredimiR technology offers a novel approach by providing a non-invasive blood test based on the estimation of serum miRNA-622 concentration using a RT-qPCR-based method that is simple, fast, cost-effective and easy to implement routinely in most clinical biology laboratories. This clinically validated technology enables prediction and monitoring of response to platinum-based chemotherapy and/or PARP inhibitors, in order to personalize therapies used in the management of ovarian carcinomas, whether during initial treatment, follow-up or relapse.
The test has been extensively validated on several clinical cohorts at baseline and after relapse.
We are looking for a licensee or a co-development deal.
-
expand_more library_books References (1)
- Nicolas Vigneron, Mégane Vernon, Matthieu Meryet-Figuière, Bernard Lambert, Mélanie Briand, Marie-Hélène Louis, Sophie Krieger, Florence Joly, Stéphanie Lheureux, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain, Christophe Denoyelle (2020), Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma, Clinical Chemistry
-
expand_more cloud_download Supporting documents (2)One-pager PredimiR.pdf (222 KB)One-pager PredimiR (fr).pdf (297 KB)